STAT Plus: 5 questions for Gilead’s rookie CEO on his Wall Street debut
AP
Daniel O’Day is getting about $30 million to save the stagnant Gilead Sciences. On Thursday, investors get their first chance to decide if he’s worth it.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario